Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000323 · ClinicalTrials.gov registry record
Therapeutic Potential of Kappa-Opioids Against Cocaine - 1
A clinical trial of Cocaine-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT00000323: Completed study of Cocaine-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).
NCT00000323 is a study of Cocaine-Related Disorders that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 10 participants, below the 64-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000323, a study of Cocaine-Related Disorders, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to characterize the effects of enadoline compared to hydromorphone and butorphanol.
Conditions Studied
Study Locations (1)
Maryland
- Johns Hopkins University (BPRU) Bayview Campus - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 1996-07 |
| Est. Completion | 1998-12 |
What the finished NCT00000323 record still lists
NCT00000323 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 64-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Cocaine-Related Disorders appearing as the primary indexed condition, and to 0 interventions.
NCT00000323 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00000323 about?
NCT00000323 is a clinical study titled "Therapeutic Potential of Kappa-Opioids Against Cocaine - 1". The purpose of this study is to characterize the effects of enadoline compared to hydromorphone and butorphanol.
What is the current status of trial NCT00000323?
This trial is currently completed. The enrollment target is 10 participants. The study started on 1996-07. Estimated completion is 1998-12.
What conditions does trial NCT00000323 study?
This clinical trial studies the following conditions: Cocaine-Related Disorders.
Who is sponsoring clinical trial NCT00000323?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000323 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000323's enrollment target sits among peer trials
10 13th of 15 higher than 3 of 15 other Cocaine-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cocaine-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Progesterone for the Treatment of Cocaine Dependence - 1
COMPLETED · NA
-
Modeling Impaired Judgement in Cocaine Abusers - 6
COMPLETED · Phase 4
-
Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention
COMPLETED · Phase 2
-
Quetiapine for Cocaine Use and Cravings
COMPLETED · Phase 4
-
Dose Response Trial of Pergolide for Cocaine Dependence - 1
COMPLETED · Phase 3
-
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia